Genentech, a Roche Group member, announced positive Phase Ib trial results for CT-388, a dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes. Over 24 weeks, a weekly CT-388 injection led to a significant mean placebo-adjusted weight loss of 18.8% (p < 0.001). All participants achieved >5% weight loss, 70% achieved >15%, and 45% achieved >20%. Additionally, CT-388 normalized glycemia in all pre-diabetic participants, showing a strong impact on glucose homeostasis. No new safety issues were identified.
Like
Save
Share